Page last updated: 2024-09-03

gefitinib and Androgen-Independent Prostatic Cancer

gefitinib has been researched along with Androgen-Independent Prostatic Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anand, A; Carver, B; Heller, G; Larson, SM; Morris, MJ; Rathkopf, DE; Rosen, N; Scher, HI; Shaffer, DR; Slovin, SF	1

Trials

1 trial(s) available for gefitinib and Androgen-Independent Prostatic Cancer

Article	Year
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer, 2015, Nov-01, Volume: 121, Issue:21 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Everolimus; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Receptors, Androgen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome	2015

Article

Year

Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Cancer, 2015, Nov-01, Volume: 121, Issue:21

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Everolimus; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Receptors, Androgen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome

2015